

Blueteq forms available for High Cost Drugs for NHS Northamptonshire CCG

Drug Name	Blueteq form Name
Abatacept	ABATACEPT for RHEUMATOID ARTHRITIS - INITIATION (NICE TA375)
Abatacept	ABATACEPT for RHEUMATOID ARTHRITIS - CONTINUATION - for patients who have been successfully treated with Abatacept as per NICE TA 375
Adalimumab	ADALIMUMAB - INITIATION for moderately to severely active ULCERATIVE COLITIS (NICE TA 329)
Adalimumab	ADALIMUMAB - CONTINUATION for moderately to severely active ULCERATIVE COLITIS (NICE TA 329)
Adalimumab	ADALIMUMAB - INITIATION for severe active CROHN'S DISEASE (NICE TA 187)
Adalimumab	ADALIMUMAB CONTINUATION FORM for Severe Active CROHN'S DISEASE (NICE TA 187)
Adalimumab	ADALIMUMAB for active PSORIATIC ARTHRITIS - INITIATION (NICE TA199)
Adalimumab	ADALIMUMAB for active PSORIATIC ARTHRITIS - CONTINUATION (NICE TA199)
Adalimumab	ADALIMUMAB for ANKYLOSING SPONDYLITIS - INITIATION (NICE TA 383)
Adalimumab	ADALIMUMAB for ANKYLOSING SPONDYLITIS - CONTINUATION (NICE TA 383)
Adalimumab	ADALIMUMAB for Non-Radiographic AXIAL SPONDYLOARTHRITIS - INITIATION (NICE TA 383)
Adalimumab	ADALIMUMAB for AXIAL SPONDYLOARTHRITIS - CONTINUATION (NICE TA 383)
Adalimumab	ADALIMUMAB for RHEUMATOID ARTHRITIS - INITIATION 40mg every other week only. (NICE TA375) Dose intensification will require a new form
Adalimumab	ADALIMUMAB for RHEUMATOID ARTHRITIS - CONTINUATION - for patients who have been successfully treated with Adalimumab as per NICE TA 375
Adalimumab	ADALIMUMAB for RHEUMATOID ARTHRITIS - DOSE INTENSIFICATION to 40mg WEEKLY. MONOTHERAPY ONLY. For patients who experience a decrease in response to standard dose
Adalimumab	ADALIMUMAB for Severe PSORIASIS - INITIATION (NICE TA 146)
Adalimumab	ADALIMUMAB for Severe PSORIASIS - CONTINUATION (NICE TA 146)
Aflibercept	Aflibercept (Eylea) for the treatment of wet age-related macular degeneration LEFT EYE (NICE TA 294) INITIATION
Aflibercept	Aflibercept (Eylea) for the treatment of wet age-related macular degeneration RIGHT EYE (NICE TA 294) INITIATION
Aflibercept	AFLIBERCEPT (Eylea) for the treatment of wet age-related macular degeneration LEFT EYE (NICE TA 294) CONTINUATION
Aflibercept	AFLIBERCEPT (Eylea) for the treatment of wet age-related macular degeneration RIGHT EYE (NICE TA 294) CONTINUATION
Aflibercept	AFLIBERCEPT (Eylea) - SWITCH for patients requiring >7 doses per year of ranibizumab for wet AMD LEFT EYE

Aflibercept	AFLIBERCEPT (Eylea) - SWITCH for patients requiring >7 doses per year of ranibizumab for wet AMD RIGHT EYE
Aflibercept	Aflibercept (Eylea) for the treatment of Diabetic macular oedema LEFT EYE (NICE TA 346) INITIATION
Aflibercept	Aflibercept (Eylea) for the treatment of Diabetic macular oedema RIGHT EYE (NICE TA 346) INITIATION
Aflibercept	Aflibercept (Eylea) for the treatment of Diabetic macular oedema LEFT EYE (NICE TA 346) CONTINUATION
Aflibercept	Aflibercept (Eylea) for the treatment of Diabetic macular oedema RIGHT EYE (NICE TA 346) CONTINUATION
Aflibercept	AFLIBERCEPT (EYLEA) for the treatment of macular oedema secondary to BRANCH retinal vein occlusion LEFT EYE INITIATION (NICE TA 409)
Aflibercept	AFLIBERCEPT (EYLEA) for the treatment of macular oedema secondary to BRANCH retinal vein occlusion RIGHT EYE INITIATION (NICE TA 409)
Aflibercept	AFLIBERCEPT (EYLEA) for the treatment of macular oedema secondary to BRANCH retinal vein occlusion LEFT EYE CONTINUATION (NICE TA 409)
Aflibercept	AFLIBERCEPT (EYLEA) for the treatment of macular oedema secondary to BRANCH retinal vein occlusion RIGHT EYE CONTINUATION (NICE TA 409)
Aflibercept	AFLIBERCEPT (EYLEA) for the treatment of macular oedema secondary to CENTRAL retinal vein occlusion LEFT EYE INITIATION (NICE TA 305)
Aflibercept	AFLIBERCEPT (EYLEA) for the treatment of macular oedema secondary to CENTRAL retinal vein occlusion RIGHT EYE INITIATION (NICE TA 305)
Aflibercept	AFLIBERCEPT (EYLEA) for the treatment of macular oedema secondary to CENTRAL retinal vein occlusion LEFT EYE CONTINUATION (NICE TA 305)
Aflibercept	AFLIBERCEPT (EYLEA) for the treatment of macular oedema secondary to CENTRAL retinal vein occlusion RIGHT EYE CONTINUATION (NICE TA 305)
Aflibercept	AFLIBERCEPT for treating CHOROIDAL NEOVASCULARISATION LEFT EYE (NICE TA 486)
Aflibercept	AFLIBERCEPT for treating CHOROIDAL NEOVASCULARISATION RIGHT EYE (NICE TA 486)
Alirocumab	ALIROCUMAB in FAMILIAL HETEROZYGOUS HYPERCHOLESTEROLAEMIA (NICE TA 393)
Alirocumab	ALIROCUMAB in PRIMARY, NON-FAMILIAL HYPERCHOLESTEROLAEMIA (NICE TA 393)
Apremilast	APREMILAST for active PSORIATIC ARTHRITIS (NICE TA433) - INITIATION FORM.
Apremilast	APREMILAST for active PSORIATIC ARTHRITIS (NICE TA433) CONTINUATION FORM
Apremilast	APREMILAST for Moderate to Severe plaque PSORIASIS. (NICE TA 419) - INITIATION.
Apremilast	APREMILAST for Moderate to Severe plaque PSORIASIS. (NICE TA 419) CONTINUATION
Baricitinib	BARICITINIB for RHEUMATOID ARTHRITIS - INITIATION (NICE TA 466)

Baricitinib	BARICITINIB for RHEUMATOID ARTHRITIS - CONTINUATION - for patients who have been successfully treated with BARICITINIB as per NICE TA 466
Botulinum toxin	Botulinum toxin A for the treatment of Urinary Incontinence in adults (NICE CG 97, 148, 171). NEW PATIENTS
Botulinum toxin	Botulinum toxin A for the treatment of Urinary Incontinence in adults (NICE CG 97, 148, 171). CONTINUATION FORM ONLY
Botulinum toxin	BOTULINUM TOXIN TYPE A for the prevention of headaches in adults with CHRONIC MIGRAINE - NEW PATIENTS (NICE TA 260)
Brodalumab	BRODALUMAB for Moderate to Severe plaque PSORIASIS. (NICE TA 511) - INITIATION.
Brodalumab	BRODALUMAB for Moderate to Severe plaque PSORIASIS. (NICE TA 511) CONTINUATION
Certolizumab	CERTOLIZUMAB PEGOL for active PSORIATIC ARTHRITIS - INITIATION (NICE TA445)
Certolizumab	CERTOLIZUMAB PEGOL for active PSORIATIC ARTHRITIS - CONTINUATION (NICE TA 445)
Certolizumab	CERTOLIZUMAB PEGOL for ANKYLOSING SPONDYLITIS - INITIATION (NICE TA 383)
Certolizumab	CERTOLIZUMAB PEGOL for ANKYLOSING SPONDYLITIS - CONTINUATION (NICE TA 383)
Certolizumab	CERTOLIZUMAB PEGOL for Non-Radiographic AXIAL SPONDYLOARTHRITIS - INITIATION (NICE TA 383)
Certolizumab	CERTOLIZUMAB PEGOL for AXIAL SPONDYLOARTHRITIS - CONTINUATION (NICE TA 383)
Certolizumab	CERTOLIZUMAB PEGOL for Moderate to Severe plaque PSORIASIS. (NICE TA 574) - INITIATION
Certolizumab	CERTOLIZUMAB PEGOL for Moderate to Severe plaque PSORIASIS. (NICE TA 574) CONTINUATION
Certolizumab	CERTOLIZUMAB PEGOL for RHEUMATOID ARTHRITIS - INITIATION (NICE TA375)
Certolizumab	CERTOLIZUMAB PEGOL for RA after inadequate response to a TNF inhibitor- INITIATION (NICE TA 415)
Certolizumab	CERTOLIZUMAB PEGOL for RHEUMATOID ARTHRITIS - CONTINUATION - for patients who have been successfully treated with certolizumab pegol as per NICE TA 375 or NICE TA 415
Dexamethasone implant (Ozurdex)	Dexamethasone implant (Ozurdex) for the treatment of macular oedema secondary to BRANCH retinal vein occlusion LEFT EYE (NICE TA 229)
Dexamethasone implant (Ozurdex)	Dexamethasone implant (Ozurdex) for the treatment of macular oedema secondary to BRANCH retinal vein occlusion RIGHT EYE (NICE TA 229)
Dexamethasone implant (Ozurdex)	Dexamethasone implant (Ozurdex) for the treatment of macular oedema secondary to CENTRAL retinal vein occlusion LEFT EYE (NICE TA 229)
Dexamethasone implant (Ozurdex)	Dexamethasone implant (Ozurdex) for the treatment of macular oedema secondary to CENTRAL retinal vein occlusion RIGHT EYE (NICE TA 229)
Dexamethasone implant (Ozurdex)	Dexamethasone implant (Ozurdex) for the treatment of UVEITIS in the LEFT EYE (NICE TA 460)
Dexamethasone	Dexamethasone implant (Ozurdex) for the treatment of UVEITIS in the RIGHT EYE (NICE TA 460)

implant (Ozurdex)	
Dimethyl Fumarate	DIMETHYL FUMARATE for Moderate to Severe plaque PSORIASIS. (NICE TA 475) - INITIATION.
Dimethyl Fumarate	DIMETHYL FUMARATE for Moderate to Severe plaque PSORIASIS. (NICE TA 475) CONTINUATION
Dupilumab	DUPILUMAB for Moderate to Severe plaque ATOPIC DERMATITIS. (NICE TA 534) - INITIATION.
Dupilumab	DUPILUMAB for Moderate to Severe ATOPIC DERMATITIS. (NICE TA 534) CONTINUATION
Etanercept	ETANERCEPT (BENEPALI) for active PSORIATIC ARTHRITIS - INITIATION (NICE TA199)
Etanercept	ETANERCEPT (BENEPALI) for active PSORIATIC ARTHRITIS - CONTINUATION (NICE TA199)
Etanercept	ETANERCEPT (BENEPALI) for ANKYLOSING SPONDYLITIS - INITIATION (NICE TA 383)
Etanercept	ETANERCEPT (BENEPALI) for ANKYLOSING SPONDYLITIS - CONTINUATION (NICE TA 383)
Etanercept	ETANERCEPT (BENEPALI) for Non-Radiographic AXIAL SPONDYLOARTHRITIS - INITIATION (NICE TA 383)
Etanercept	ETANERCEPT (BENEPALI) for AXIAL SPONDYLOARTHRITIS - CONTINUATION (NICE TA 383)
Etanercept	ETANERCEPT (BENEPALI) for RHEUMATOID ARTHRITIS 50mg weekly - INITIATION (NICE TA375)
Etanercept	ETANERCEPT (BENEPALI) for RHEUMATOID ARTHRITIS - CONTINUATION - for patients who have been successfully treated with Etanercept as per NICE TA 375
Etanercept	ETANERCEPT (ENBREL) for RHEUMATOID ARTHRITIS - CONTINUATION - for patients who have been successfully treated with Etanercept as per NICE TA 375
Etanercept	ETANERCEPT (BENEPALI) for Severe PSORIASIS 50mg weekly - INITIATION (NICE TA 146)
Etanercept	ETANERCEPT (BENEPALI) for Severe PSORIASIS - CONTINUATION (NICE TA 146)
Evolocumab	EVOLOCUMAB in FAMILIAL HETEROZYGOUS HYPERCHOLESTEROLAEMIA (NICE TA 394)
Evolocumab	EVOLOCUMAB in PRIMARY, NON-FAMILIAL HYPERCHOLESTEROLAEMIA (NICE TA 394)
Fluocinolone implant (Iluvien)	Fluocinolone implant (iluvien) for the treatment of Diabetic macular oedema LEFT EYE (NICE TA 301)
Fluocinolone implant (Iluvien)	Fluocinolone implant (iluvien) for the treatment of Diabetic macular oedema RIGHT EYE (NICE TA 301)
Golimumab	GOLIMUMAB for active PSORIATIC ARTHRITIS - INITIATION (NICE TA220)
Golimumab	GOLIMUMAB for active PSORIATIC ARTHRITIS - CONTINUATION (NICE TA 220)
Golimumab	GOLIMUMAB- INITIATION for moderately to severely active ULCERATIVE COLITIS (NICE TA 329)
Golimumab	GOLIMUMAB - CONTINUATION for moderately to severely active ULCERATIVE COLITIS (NICE TA 329)
Golimumab	GOLIMUMAB for ANKYLOSING SPONDYLITIS - INITIATION (NICE TA 383)
Golimumab	GOLIMUMAB for ANKYLOSING SPONDYLITIS - CONTINUATION (NICE TA 383)
Golimumab	GOLIMUMAB for NON-RADIOGRAPHIC AXIAL

	SPONDYLOARTHRITIS - INITIATION (NICE TA 497)
Golimumab	GOLIMUMAB for NON RADIOGRAPHIC SPONDYLOARTHRITIS-CONTINUATION (NICE TA 497)
Golimumab	GOLIMUMAB for RHEUMATOID ARTHRITIS - INITIATION (NICE TA375)
Golimumab	GOLIMUMAB for RHEUMATOID ARTHRITIS - CONTINUATION - for patients who have been successfully treated with Abatacept as per NICE TA 375
Golimumab	GOLIMUMAB for Non-Radiographic AXIAL SPONDYLOARTHRITIS - INITIATION (NICE TA 497)
Golimumab	GOLIMUMAB for non-radiographic axial spondyloarthritis CONTINUATION as per NICE TA 497
Guselkumab	GUSELKUMAB for Moderate to Severe plaque PSORIASIS. (NICE TA 521) - INITIATION.
Guselkumab	GUSELKUMAB for Moderate to Severe plaque PSORIASIS. (NICE TA 521) CONTINUATION
Infliximab (Inflectra)	INFLIXIMAB (INFLECTRA) - INITIATION - for Severe Active CROHN'S DISEASE or FISTULISING CROHN'S DISEASE (NICE TA 187)
Infliximab (Inflectra)	INFLIXIMAB (INFLECTRA) CONTINUATION FORM for Severe Active CROHN'S DISEASE or FISTULISING CROHN'S DISEASE (NICE TA 187)
Infliximab (Remsima)	INFLIXIMAB (REMSIMA) - INITIATION - for Severe Active CROHN'S DISEASE or FISTULISING CROHN'S DISEASE (NICE TA 187)
Infliximab (Remsima)	INFLIXIMAB (REMSIMA) CONTINUATION FORM for Severe Active CROHN'S DISEASE or FISTULISING CROHN'S DISEASE (NICE TA 187)
Infliximab (Remicade)	INFLIXIMAB (REMICADE) CONTINUATION FORM for Severe Active CROHN'S DISEASE or FISTULISING CROHN'S DISEASE (NICE TA 187)
Infliximab (Inflectra)	INFLIXIMAB (INFLECTRA) for Acute Severely Active ULCERATIVE COLITIS (NICE TA 163)
Infliximab (Remsima)	INFLIXIMAB (REMSIMA) for Acute Severely Active ULCERATIVE COLITIS (NICE TA 163)
Infliximab (Inflectra)	INFLIXIMAB (INFLECTRA) - INITIATION for moderately to severely active ULCERATIVE COLITIS (NICE TA 329)
Infliximab (Inflectra)	INFLIXIMAB (INFLECTRA) - CONTINUATION for moderately to severely active ULCERATIVE COLITIS (NICE TA 329)
Infliximab (Remsima)	INFLIXIMAB (REMSIMA) - INITIATION for moderately to severely active ULCERATIVE COLITIS (NICE TA 329)
Infliximab (Remsima)	INFLIXIMAB (REMSIMA) CONTINUATION FORM for Severe Active CROHN'S DISEASE or FISTULISING CROHN'S DISEASE (NICE TA 187)
Infliximab (Remicade)	INFLIXIMAB (REMICADE) - CONTINUATION for moderately to severely active ULCERATIVE COLITIS (NICE TA 329)
Infliximab (Inflectra)	INFLIXIMAB (INFLECTRA) for active PSORIATIC ARTHRITIS - INITIATION (NICE TA199)
Infliximab (Inflectra)	INFLIXIMAB (INFLECTRA) for active PSORIATIC ARTHRITIS - CONTINUATION (NICE TA199)
Infliximab (Remsima)	INFLIXIMAB (REMSIMA) for active PSORIATIC ARTHRITIS - INITIATION (NICE TA199)
Infliximab (Remsima)	INFLIXIMAB (REMSIMA) for active PSORIATIC ARTHRITIS - CONTINUATION (NICE TA199)
Infliximab (Inflectra)	INFLIXIMAB (INFLECTRA) for very severe PSORIASIS - INITIATION (NICE TA 134)

Infliximab (Inflectra)	INFLIXIMAB (INFLECTRA) for very severe PSORIASIS - CONTINUATION (NICE TA 134)
Infliximab (Inflectra)	INFLIXIMAB (INFLECTRA) for RHEUMATOID ARTHRITIS - INITIATION (NICE TA 375)
Infliximab (Remsima)	INFLIXIMAB (REMSIMA) for very severe PSORIASIS - INITIATION (NICE TA 134)
Infliximab (Remsima)	INFLIXIMAB (REMSIMA) for very severe PSORIASIS - CONTINUATION (NICE TA 134)
Infliximab (Inflectra)	INFLIXIMAB (INFLECTRA) for RHEUMATOID ARTHRITIS - CONTINUATION - for patients who have been successfully treated with Infliximab as per NICE TA 375
Infliximab (Remsima)	INFLIXIMAB (REMSIMA) for ANKYLOSING SPONDYLITIS - INITIATION (NICE TA 383)
Infliximab (Remsima)	INFLIXIMAB (REMSIMA) for ANKYLOSING SPONDYLITIS - CONTINUATION (NICE TA 383)
Infliximab (Remsima)	INFLIXIMAB (REMSIMA) for RHEUMATOID ARTHRITIS - INITIATION (NICE TA 375)
Infliximab (Remsima)	INFLIXIMAB (REMSIMA) for RHEUMATOID ARTHRITIS - CONTINUATION - for patients who have been successfully treated with Infliximab as per NICE TA 375
Ixelizumab	IXEKIZUMAB for active PSORIATIC ARTHRITIS - INITIATION(NICE TA 537)
Ixelizumab	IXEKIZUMAB for active PSORIATIC ARTHRITIS - CONTINUATION (NICE TA 537)
Ixelizumab	IXEKIZUMAB for Moderate to Severe plaque PSORIASIS. (NICE TA 442) - INITIATION.
Ixelizumab	IXEKIZUMAB for Moderate to Severe plaque PSORIASIS. (NICE TA 442) CONTINUATION
Ocriplasmin (Jetrea)	Ocriplasmin (Jetrea) for the treatment of vitreomacular traction LEFT EYE (NICE TA 297)
Ocriplasmin (Jetrea)	Ocriplasmin (Jetrea) for the treatment of vitreomacular traction RIGHT EYE (NICE TA 297)
Omalizumab	OMALIZUMAB for previously treated CHRONIC SPONTANEOUS URTICARIA (NICE TA 339)
Ranibizumab	Ranibizumab (Lucentis) for the treatment of Choroidal neovascularisation secondary to pathologic myopia LEFT EYE (NICE TA 298)
Ranibizumab	Ranibizumab (Lucentis) for the treatment of Choroidal neovascularisation secondary to pathologic myopia RIGHT EYE (NICE TA 298)
Ranibizumab	Ranibizumab (Lucentis) for the treatment of macular oedema secondary to BRANCH retinal vein occlusion LEFT EYE CONTINUATION (NICE TA 283)
Ranibizumab	Ranibizumab (Lucentis) for the treatment of macular oedema secondary to BRANCH retinal vein occlusion LEFT EYE (NICE TA 283)
Ranibizumab	RANIBIZUMAB (LUCENTIS) for the treatment of macular oedema secondary to BRANCH retinal vein occlusion RIGHT EYE CONTINUATION (NICE TA 283)
Ranibizumab	Ranibizumab (Lucentis) for the treatment of macular oedema secondary to BRANCH retinal vein occlusion RIGHT EYE INITIATION (NICE TA 283)
Ranibizumab	RANIBIZUMAB (LUCENTIS) for the treatment of macular oedema secondary to CENTRAL retinal vein occlusion LEFT EYE CONTINUATION (NICE TA 283)
Ranibizumab	RANIBIZUMAB (LUCENTIS) for the treatment of macular oedema

	secondary to CENTRAL retinal vein occlusion RIGHT EYE CONTINUATION (NICE TA 283)
Ranibizumab	Ranibizumab (Lucentis) for the treatment of macular oedema secondary to CENTRAL retinal vein occlusion LEFT EYE (NICE TA 283)
Ranibizumab	Ranibizumab (Lucentis) for the treatment of macular oedema secondary to CENTRAL retinal vein occlusion RIGHT EYE INITIATION (NICE TA 283)
Ranibizumab	Ranibizumab (Lucentis) for the treatment of Diabetic macular oedema LEFT EYE (NICE TA 274) CONTINUATION
Ranibizumab	Ranibizumab (Lucentis) for the treatment of Diabetic macular oedema LEFT EYE (NICE TA 274) INITIATION
Ranibizumab	Ranibizumab (Lucentis) for the treatment of Diabetic macular oedema RIGHT EYE (NICE TA 274) CONTINUATION
Ranibizumab	Ranibizumab (Lucentis) for the treatment of Diabetic macular oedema RIGHT EYE (NICE TA 274) INITIATION
Ranibizumab	Ranibizumab (Lucentis) for the treatment of Diabetic macular oedema RIGHT EYE (NICE TA 274) INITIATION
Ranibizumab	Ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration LEFT EYE (NICE TA 155) INITIATION
Ranibizumab	Ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration RIGHT EYE (NICE TA 155) INITIATION
Ranibizumab	Ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration RIGHT EYE (NICE TA 155) CONTINUATION
Risankizumab	RISANKIZUMAB for Moderate to Severe plaque PSORIASIS. (NICE TA 596) - INITIATION.
Risankizumab	RISANKIZUMAB for Moderate to Severe plaque PSORIASIS. (NICE TA 596) CONTINUATION
Rituximab (Mabthera)	RITUXIMAB - MABTHERA - INITIATION for rheumatoid arthritis after inadequate response or intolerance to other drugs including a TNF alpha inhibitor (NICE TA 195)
Rituximab (Truxima)	RITUXIMAB - TRUXIMA - INITIATION for rheumatoid arthritis after inadequate response or intolerance to other drugs including a TNF alpha inhibitor (NICE TA 195)
Sarilumab	SARILUMAB for RHEUMATOID ARTHRITIS - INITIATION (NICE TA 485)
Sarilumab	SARILUMAB for RHEUMATOID ARTHRITIS - CONTINUATION - for patients who have been successfully treated with tocilizumab as per NICE TA 485
Secukinumab	SECUKINUMAB for active PSORIATIC ARTHRITIS - INITIATION (NICE TA445)
Secukinumab	SECUKINUKAB for active PSORIATIC ARTHRITIS - CONTINUATION (NICE TA 445)
Secukinumab	SECUKINUMAB for ANKYLOSING SPONDYLITIS - INITIATION (NICE TA 407)
Secukinumab	SECUKINUMAB for ANKYLOSING SPONDYLITIS - CONTINUATION (NICE TA 383)
Secukinumab	SECUKINUMAB for Moderate to Severe plaque PSORIASIS. (NICE TA 350) - INITIATION.
Secukinumab	SECUKINUMAB for Moderate to Severe plaque PSORIASIS. (NICE TA 350) CONTINUATION
Tildrakizumab	TILDRAKIZUMAB for Moderate to Severe plaque PSORIASIS. (NICE TA 575) - INITIATION
Tildrakizumab	TILDRAKIZUMAB for Moderate to Severe plaque PSORIASIS. (NICE TA 575) CONTINUATION
Tocilizumab	TOCILIZUMAB for RHEUMATOID ARTHRITIS - INITIATION (NICE

	TA375)
Tocilizumab	TOCILIZUMAB for RHEUMATOID ARTHRITIS - CONTINUATION - for patients who have been successfully treated with tocilizumab as per NICE TA 375
Tofacitinib	TOFACITINIB for RHEUMATOID ARTHRITIS - CONTINUATION - for patients who have been successfully treated with TOFACITINIB as per NICE TA 480
Tofacitinib	TOFACITINIB - INITIATION for treating moderately to severely active ulcerative colitis (NICE TA 547)
Tofacitinib	TOFACITINIB for active PSORIATIC ARTHRITIS - INITIATION (NICE TA 543)
Tofacitinib	TOFACITINIB for active PSORIATIC ARTHRITIS - CONTINUATION (NICE TA 543)
Tolvaptan	TOLVAPTAN for Treating Autosomal Dominant Polycystic Kidney Disease in Adults (NICE TA 358)
Ustekinumab	USTEKINUMAB - INITIATION for moderately to severely active CROHN'S DISEASE (NICE TA 456) after previous treatment
Ustekinumab	USTEKINUMAB CONTINUATION FORM for moderately to severely active CROHN'S DISEASE (NICE TA 456)
Ustekinumab	USTEKINUMAB for active PSORIATIC ARTHRITIS - INITIATION (NICE TA340)
Ustekinumab	USTEKINUMAB for active PSORIATIC ARTHRITIS - CONTINUATION (NICE TA 340)
Ustekinumab	USTEKINUMAB for Severe PLAQUE PSORIASIS - INITIATION (NICE TA 180)
Ustekinumab	USTEKINUMAB for Severe PLAQUE PSORIASIS - CONTINUATION (NICE TA 180)
Vedolizumab	VEDOLIZUMAB - INITIATION for treating moderately to severely active ulcerative colitis (NICE TA 342)
Vedolizumab	VEDOLIZUMAB - CONTINUATION for moderately to severely active ULCERATIVE COLITIS (NICE TA 342)
Vedolizumab	VEDOLIZUMAB - INITIATION for moderately to severely active CROHN'S DISEASE (NICE TA 352) after prior therapy
Vedolizumab	VEDOLIZUMAB CONTINUATION FORM for moderately to severely active CROHN'S DISEASE (NICE TA 352)